VYNE Therapeutics Inc. 8-K

What Happened

• VYNE Therapeutics Inc. announced on January 30, 2026 that it, its wholly‑owned subsidiary Yarrow Merger Sub Corp., and Yarrow Bioscience, Inc. entered into Amendment No. 1 to the Agreement and Plan of Merger and Reorganization originally dated December 17, 2025.
• The amendment document was filed as Exhibit 10.1 to VYNE’s Form 8‑K.

Key Details

• Amendment executed: January 30, 2026.
• Original merger agreement date: December 17, 2025.
• Parties to the amendment: VYNE Therapeutics Inc., Yarrow Merger Sub Corp. (a VYNE subsidiary), and Yarrow Bioscience, Inc.
• Amendment filed as Exhibit 10.1 to the Form 8‑K.

Why It Matters

• An amendment to a merger agreement is a material corporate action because it modifies the legal terms governing the merger (for example timing, conditions, or obligations). Investors should review the filed amendment (Exhibit 10.1) to see what specific changes were made and watch for further SEC filings or company announcements that disclose impacts on closing, timing, or deal structure.